FLT3 and acute myeloid leukemia: It is in this context that second generation FLT3 inhibitors which are more specific and have potency as monotherapy, even in relapsed refractory AML such as Quizartinib and Gilteritinib (91, 92) may be important as maintenance post allo-SCT, and the results of the BMT-CTN 1506 study which compares Gilteritinib to control post allo-SCT and has completed accrual, is eagerly awaited.